For non-small cell lung cancer, amgen KRAS G12C inhibitor Phase III study reached the primary endpoint

On August 30, Amgen announced that its KRAS G12C inhibitor Lumakras (sotorasib) met the primary endpoint in a phase III CodeBreaK 200 clinical study treating treated patients with treated non-small cell lung cancer with KRAS G12C mutations: Lumakras significantly improved progression-free survival (PFS) compared with standard chemotherapy (intravenous docetaxel).

From: The official website of the enterprise

The CodeBreaK 200 study is a global randomized controlled Phase III clinical trial to evaluate the efficacy and safety of Lumakras in 345 patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) compared to standard chemotherapy who had previously received at least one platinum-containing chemotherapy and immune checkpoint inhibitor

Amgen said detailed data from the experiment will be shared

According to the Insight database, Lumakras was launched in May 2021 through the ACCELERATED APPROVAL ROUTE by the US FDA, becoming the first KRAS targeted therapy approved after nearly 40 years of research, and Lumakras is also the first targeted therapy

At present, Amgen is also exploring the efficacy of Lumakras in combination with other drugs, and is conducting a number of clinical studies

In July, Amgen disclosed part of lumakras' SHP2 inhibitor RMC-4630 in Sanofi/Revolution Medicines: of the 11 NSCLC patients, three (27 percent) achieved partial remission (PR), of which 2 were in continued remission at the time of data cut-off and 7 (64 percent) achieved disease control

In August, Amgen disclosed the first phase of data on the safety and efficacy of Lumakras in combination with K and T drugs

Results of the CodeBreaK 100/CodeBreaK 101 clinical trial

From: Insight Database Web (http://db.